Objective To determine the efficacy and safety of oral etoposide on metastatic breast cancer.
Methods In this retrospective trial, 88 metastatic breast cancer (MBC) patients received oral etoposide 50 mg/d on days 1-20 every 28 days.
Results A total of 88 patients with MBC were enrolled, 83.0%(73/88) of the patients received multiple line (≥3 lines) chemotherapy, and 78.4%(69/88) of the patients had been pretreated with anthracycline, taxane, and capecitabine. All patients received median five cycles of oral etoposide therapy and all were evaluable for response, 7(8.0%) patients achieved partial response (PR), 50(56.8%) patients had stable disease (SD), 31(35.2%) had progressive disease (PD) and no one achieved complete response (CR). The objective response rate (ORR, CR+PR) was 8.0% and the clinical benefit rate (CBR, CR+PR+SD≥6.0 months) was 44.3%. Median progression free survival (PFS) was 5.0 months (95%CI: 3.8-6.2 months). Median overall survival (OS) was 17.0 months (95%CI: 11.3-22.7 months). The main toxicities were grade 1-2 nausea (20.5%), grade 1-2 neutropenia (21.6%), grade 3 neutropenia (3.4%).
Conclusion Oral etoposide could be an option with efficacy and safety for heavily pretreated metastatic breast cancer.
DownLoad: